Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
SA55 Injection
DRUG
2 trials
Sponsors
Sinovac Life Sciences Co., Ltd.
Conditions
COVID-19
Infection of Upper Respiratory Tract Caused by 2019-nCoV
Phase 1
SA55 Injection: a Potential Therapy for the Prevention and Treatment of COVID-19
NCT06050460
Sinovac Life Sciences Co., Ltd.
COVID-19
Start: 2023-06-15
End: 2023-12-30
Target: 40
Updated: 2023-09-22
Phase 2
SA55 Injection Phase II Study in the Treatment of Mild/Moderate COVID-19 Patients
NCT06042764
Sinovac Life Sciences Co., Ltd.
Infection of Upper Respiratory Tract Caused by 2019-nCoV
Start: 2023-08-31
End: 2024-08-30
Target: 150
Updated: 2023-12-12
Related Papers
Safety, tolerability, and pharmacokinetics of anti-SARS-CoV-2 monoclonal antibody SA55 injection in healthy participants
Antimicrobial Agents and Chemotherapy
2025-07-17